Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769663 | 0.89 | HRH4 (0.49) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25759304 | 0.88 | HRH4 (0.49) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL24112775 | 0.85 | HRH4 (0.54) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL24754511 | 0.82 | HRH4 (0.46) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25769740 | 0.79 | IDO1 (0.49) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25759303 | 0.79 | HRH4 (0.50) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25759249 | 0.78 | HRH4 (0.51) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL24754738 | 0.78 | HRH4 (0.51) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25759306 | 0.78 | HRH4 (0.50) | HRH4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL25759259 | 0.78 | HRH4 (0.53) | HRH4DRD2DRD3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HRH4 4259/4885DRD2 4609/4885DRD3 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.